TCR-T cell therapy (Anocca AB)

N/A

Report date: 2025/06/11 10:55:02

Base Information

Drug NameTCR-T cell therapy (Anocca AB)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHuman leukocyte antigen modulatorsT lymphocytes stimulantsImmunostimulants
TargetsHuman leukocyte antigen
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAnocca AB
China Registration ClassN/A

Develop Information

Active CompaniesAnocca AB
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A